Citeline, a Norstella company

add a desc test

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

in the expanding and competitive field of obesity therapy clinical trials, one trend is increasingly causing a headache: placebo-arm participants dropping out or using “off-protocol” weight-loss treatments while on trial.

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

add a desc test

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Pink Sheet reporter and editors discuss the likely impacts of Center for Drug Evaluation and Research Director Richard Pazdur’s retirement from the FDA and Tracy Beth Høeg becoming the center’s acting director.

test podcast

Lupin’s CEO Vinita Gupta and MD Nilesh Gupta outline the company’s innovation agenda, strategy on GLP-1 drugs including fortnightly candidate bofanglutide, plans to get to number one in the domestic market and the legacy of their father in this podcast interview.